Rare Vocal Cord Metastasis From Prostate Adenocarcinoma on 68 Ga-PSMA PET/CT : A Diagnostic Mimic.

Clin Nucl MedJun 24, 2026 (epub)

Kevser Oksuzoglu, Hasan Onner

✦ AI-curated · Sources linked

Case in brief

A patient with prostate adenocarcinoma presented with a vocal cord metastasis, which was identified through 68 Ga-PSMA PET/CT imaging. This finding was notable as the metastasis remained asymptomatic for an extended duration, highlighting the unusual nature of such a presentation. The case underscores the importance of considering metastatic disease in patients with a history of prostate cancer, even when they are clinically silent.

What made this case unusual

Vocal cord metastasis from prostate adenocarcinoma is exceptionally rare, making this case noteworthy for its atypical presentation.

Diagnostic / clinical pearl

Clinicians should be aware that prostate adenocarcinoma can metastasize to the vocal cords, even in the absence of symptoms.

Why it matters

This case emphasizes the need for vigilance in monitoring patients with prostate cancer for potential metastatic sites that are not typically associated with this malignancy.

Source

Published in Clin Nucl Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Urology

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.